Obesity
60 articles on Obesity, researched and written by the Shotlee Editorial Team from primary sources.
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.
7 min read
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.
8 min read
Semaglutide for Weight Loss in Adults Over 65: New Study Findings
A recent analysis of the STEP trials reveals that semaglutide, the active ingredient in popular medications like Ozempic and Wegovy, offers significant weight loss and health benefits for adults over 65 with obesity, with a safety profile comparable to younger populations.
8 min read
Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter
Recent analysis indicates that GLP-1 weight loss medications significantly reduce the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes treatments.
8 min read
Doctors Warn a New GLP-1 Finding May Raise Your Risk of Smell Loss
Researchers analyzed nearly 877,000 patients and found a significant link between GLP-1 receptor agonists and sensory disturbances.
8 min read
I Lost 5 Stone on Mounjaro — But Now I’ve Had Enough
Natalie Lavergne transformed her health and lost 5 stone using Mounjaro, but now plans to switch to the Wegovy pill. Discover the medical realities of stopping weight loss medication.
8 min read
New “Trojan Horse” Drug Supercharges Weight Loss in Early Trials
A new hybrid molecule designed by Helmholtz Munich researchers acts as a Trojan horse to deliver metabolic compounds directly into cells, showing superior weight loss in mice compared to standard treatments.
8 min read
MOTS-C: A Peptide for Obesity Beyond GLP-1s?
While GLP-1 agonists have dominated weight loss discussions, a new peptide called MOTS-C is emerging with its own unique potential for tackling obesity and improving metabolic health. This article delves into what MOTS-C is, how it works, and its current research status.
7 min read
How GLP-1 Medications Can Affect Your Teeth
GLP-1 medications, known for their weight loss and blood sugar benefits, can also affect oral health. Learn about the common side effects and how to protect your teeth.
8 min read
Bitter Hops Extract Supplement for Weight Loss
A recent study suggests a bitter hops extract supplement, Amarasate, could aid fat loss and preserve muscle mass, offering a potential alternative or complementary approach to GLP-1 medications.
8 min read
Study Links Hormonal Birth Control Use to Higher Likelihood of Needing Weight Loss Injections
A recent Danish study suggests that women who have used hormonal birth control may be more likely to seek weight loss injections such as Wegovy and Ozempic. This research sheds light on a long-reported, yet often unproven, connection between contraceptives and weight changes.
7 min read
Eli Lilly Prepares FDA Run for ‘Triple-G’ Weight Loss Drug With Phase 3 Data
Eli Lilly has announced positive Phase 3 results for retatrutide, positioning the triple-agonist drug for an FDA filing in 2027 with substantial weight loss outcomes.
7 min read
Ozempic Lowers Calorie Intake For At Least A Year, Even If Hunger Returns, Trial Finds
A new 60-week clinical trial reveals that semaglutide continues to reduce calorie consumption significantly, even when subjective hunger sensations return to baseline levels.
7 min read
Millions Losing Weight Using GLP-1s: How Do Drugs Affect Love Lives?
As millions turn to GLP-1 medications for weight loss, unexpected changes in romantic relationships and sexual desire are emerging. This article explores the psychological and physiological impacts on love lives.
6 min read
The Billion-Dollar Problem Limiting Access to Ozempic, Wegovy, and Zepbound
Despite clinical evidence highlighting the significant health benefits and cost-effectiveness of GLP-1 medications such as Ozempic, Wegovy, and Zepbound, many insurance plans continue to impose restrictions on patient access. This article delves into the financial and practical barriers, as well as the profound consequences for individuals seeking these transformative treatments.
7 min read
Katie Lee Biegel Shares Update on 'Incredibly Positive' GLP-1 Experience
Food Network personality Katie Lee Biegel opens up about her journey with GLP-1 medications, detailing her 'incredibly positive' experience with weight loss and enhanced well-being.
10 min read
Ozempic Face and Hair Loss: Evidence for GLP-1 Drug Side Effects
Weight-loss medications like Wegovy and Mounjaro have surged in popularity, leading to increased discussions about their side effects. This article delves into the scientific evidence for frequently reported concerns such as 'Ozempic face,' hair thinning, digestive problems, and eye conditions associated with GLP-1 agonists.
11 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell discusses her 30kg weight loss using Mounjaro, the subsequent skin concerns, and the mental health benefits of GLP-1 therapy.
6 min read
Novo Nordisk Sues Eli Lilly Over Which GLP-1 Sheds the Most Pounds
Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising regarding the comparative weight loss efficacy of Zepbound and Wegovy. The dispute centers on dosage comparisons and clinical trial data interpretation.
8 min read
Fat Loss with GLP-1s, Muscle Loss Concerns: What Users Need to Know
GLP-1 medications are powerful tools for weight loss, but concerns are emerging about potential muscle mass loss. This article delves into what users need to know about preserving lean body mass and maintaining cardiorespiratory fitness alongside fat reduction.
7 min read
Eli Lilly to Seek FDA Approval for Obesity Drug Retatrutide
Eli Lilly announces plans to file for FDA approval of its triple-agonist obesity drug retatrutide in early 2027 following successful Phase 3 trial data.
8 min read
The New Drug Melting Body Fat From 38% To 22% — And The Side Effects Patients Are Ignoring
A detailed look at the case of Gary Anderton, who achieved significant weight loss using unregulated peptides, and the critical safety risks associated with this trend.
8 min read
AI Helps Stanford Scientists Discover Natural Ozempic Without the Usual Side Effects
Stanford Medicine researchers have identified a naturally occurring molecule that may suppress appetite and reduce body weight in a way that resembles semaglutide, the active ingredient in Ozempic.
8 min read
The Workforce Runs on Weight Loss Drugs? Employees on GLP-1s Take Fewer Sick Days
Employees on GLP-1 medications are taking significantly fewer sick days, leading to cost savings and improved productivity. A new study reveals the economic and health impacts of drugs like Ozempic and Wegovy on the workforce.
9 min read
China Adds Second GLP-1 Diabetes Drug to Essential Medicine List
China includes injectable semaglutide on its National Essential Drug List, improving access for diabetes patients while excluding obesity indications from the policy.
7 min read
FDA to Review 7 Popular Peptides Touted for Weight Loss, Healing and Longevity
The FDA Pharmacy Compounding Advisory Committee is set to evaluate seven peptide substances currently available through the gray market. Experts weigh in on safety, efficacy, and future patient access.
7 min read
Novo Nordisk Sues Eli Lilly, Alleging Misleading Advertising of Obesity Drugs
Novo Nordisk has filed a lawsuit against Eli Lilly in New Jersey, claiming deceptive advertising regarding GLP-1 and dual-agonist weight loss medications.
7 min read
Study Links GLP-1 Medications To Rare Vision Issue
New research indicates a possible association between GLP-1 medications, commonly prescribed for type 2 diabetes and weight management, and a rare but serious vision issue. This article explores the study's findings, potential implications, and expert recommendations.
6 min read
Semaglutide Telehealth: From The Access Boom To Regulatory Reckoning
The rapid rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity and diabetes care, generating billions in revenue for major manufacturers while creating unprecedented demand for weight management solutions. Telehealth platforms initially emerged as a critical access channel, offering convenient prescriptions and more affordable compounded versions during national shortages. Yet by 2025 and 2026, the sector faced a sharp pivot as FDA actions resolved shortages and curtailed large-scale compounding operations.
7 min read
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising Claims in Legal Battle
Novo Nordisk has filed a lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising regarding GLP-1 weight loss medications.
7 min read
US Regulators Consider Controversial Peptides Backed by RFK Jr.
The US Food and Drug Administration is evaluating the use of seven peptides, increasingly marketed for wellness and medical conditions. This review comes amidst soaring popularity, celebrity endorsements, and significant debate over their safety and efficacy.
8 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell shares her candid experience with Mounjaro, detailing her 30kg weight loss, Type 2 diabetes management, and the physical consequences of rapid fat loss.
12 min read
Ozempic Maker Novo Nordisk Sues Eli Lilly Over 'Materially Misleading' Ads
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging deceptive advertising regarding weight-loss drugs. This legal battle highlights the intense competition between semaglutide and tirzepatide.
9 min read
GLP-1s for Teen Weight Loss: A New Treatment Trend?
GLP-1 medications are rapidly changing obesity care for teens and young adults, with a notable shift away from bariatric surgery. This article delves into the latest research, potential benefits, and important considerations for this emerging trend.
7 min read
Jim Cramer on Eli Lilly Amid Rival's GLP-1 Lawsuit
Jim Cramer weighs in on Eli Lilly's position in the GLP-1 market following a lawsuit from competitor Novo Nordisk, analyzing the situation for investors.
7 min read
Medicare's New GLP-1 Weight-Loss Drug Program: What to Know
Medicare is launching a new pilot program to increase access to GLP-1 medications for weight loss, offering a $50 monthly copay for eligible beneficiaries. This marks a significant step in covering obesity as a medical condition.
9 min read
Amy Schumer Shows Off Ongoing Weight Loss, Says C-Section Scar Makes Her a 'Warrior'
Comedian Amy Schumer discusses her 50-pound weight loss journey, Cushing syndrome diagnosis, and C-section recovery in a candid new update.
10 min read
Semaglutide Greenlit for MASH Liver Disease Treatment
The MHRA has granted conditional approval for semaglutide to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
7 min read
Plus-Size Swimsuit Model on Inclusivity Amidst GLP-1 Medications
Plus-size model Hunter McGrady shares her concerns about a perceived decline in fashion inclusivity, particularly in the context of the growing popularity of GLP-1 weight loss medications.
7 min read
Which GLP-1 Works Best? New Meta-Study Puts Medications Head-to-Head
A comprehensive meta-analysis from the University of Georgia compares three major GLP-1 medications. Discover which drug offers the highest weight loss efficacy and what the data means for patients.
8 min read
Dr. Oz Links Obesity to Chronic Disease Surge, Suggests GLP-1s Can 'Jumpstart' Better Health
CMS Administrator Dr. Oz highlights the critical link between obesity and chronic diseases, advocating for the strategic use of GLP-1 medications to improve health and potentially cut healthcare costs.
7 min read
Dr. Reddy's Generic Ozempic Supplies Delayed on API Issue
Dr. Reddy's Laboratories has paused commercial production of generic semaglutide following quality concerns with the active ingredient. Here is what patients need to know about the delay and what it means for access to GLP-1 therapy.
8 min read
The Overlooked Nutrition Risks of Ozempic and Wegovy
New research from UCL and Cambridge highlights critical nutrition gaps in GLP-1 therapy. Discover the risks of muscle loss and deficiencies, and how to manage them safely.
8 min read
Amy Schumer Reveals Ongoing Weight Loss in New Selfie, Says C-Section Scar Makes Her a 'Warrior'
Comedian Amy Schumer recently shared a selfie highlighting her weight loss and C-section scar, opening up about her diagnosis of Cushing's syndrome and her path to health.
7 min read
People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less
New data presented at ENDO 2026 reveals a paradox: patients on GLP-1 medications like Ozempic and Wegovy reduced their physical activity despite losing weight.
8 min read
Yes, GLP-1s Make You Thinner. But Do They Make You Freer?
While GLP-1 drugs like Ozempic and Wegovy offer significant medical benefits, their rise raises critical questions about freedom, body image, and the cultural pressure to be thinner.
8 min read
Ozempic and Similar Weight-Loss Medications Linked to 30% Lower Breast Cancer Risk
A major study from Penn Medicine reveals a potential link between GLP-1 medications like Ozempic and a significant reduction in breast cancer risk, offering new hope for preventive care.
7 min read
GLP-1 Weight-Loss Drugs Linked to Lower Risks of Addiction and Overdose
Explore the groundbreaking research linking GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, to a reduced risk of substance use disorders and fewer addiction-related emergencies.
8 min read
Ozempic and Wegovy Use Linked to Thousands of Poison Control Calls
The widespread adoption of Ozempic and Wegovy for weight loss has coincided with a significant rise in calls to poison control centers. This article delves into the research behind this trend, highlighting common mistakes and the importance of proper patient education.
6 min read
New Weight Loss Pill Beats Oral Ozempic in Major Clinical Trial
A recent Phase 3 clinical trial indicates that orforglipron offers superior blood sugar control and weight loss compared to oral semaglutide, though side effects remain a consideration.
9 min read
Bariatric Surgery Shows 5x More Weight Loss Than GLP-1s in Real-World Study
A groundbreaking real-world comparison study presented at the ASMBS 2025 Annual Scientific Meeting found that bariatric surgery resulted in approximately five times more weight loss compared to popular GLP-1 receptor agonist medications over a two-year period. This research highlights important considerations for patients and healthcare providers navigating weight management options.
7 min read
Mounjaro's Impact on Food Cravings: A Case Study
A groundbreaking case study involving deep brain activity recordings has shed light on how tirzepatide, known as Mounjaro and Zepbound, impacts the brain's reward center and its connection to food cravings and loss of control eating.
8 min read
Managing Ozempic and Wegovy Weight Loss Side Effects: Nausea and Beyond
New research is shedding light on how GLP-1 medications, including popular drugs like Ozempic and Wegovy, influence brain pathways that control nausea, thirst, and reward-driven behaviors. This article delves into these findings and discusses potential strategies for managing common side effects.
7 min read
Semaglutide (Ozempic, Wegovy) Offers Heart Protection Beyond Weight Loss
A groundbreaking study published in The Lancet demonstrates that semaglutide, the active ingredient in Ozempic and Wegovy, provides substantial cardiovascular protection independent of the amount of weight lost. This finding reshapes our understanding of how these GLP-1 receptor agonists benefit heart health.
7 min read
Ozempic, Wegovy, and Mounjaro May Alter Taste: How Food Flavor Changes Can Impact Cravings
Discover how incretin-based therapies like Ozempic, Wegovy, and Mounjaro might be changing the way you experience food. This article delves into new research linking altered taste perception to reduced appetite and cravings, offering insights for patients and clinicians.
8 min read
The Next Ozempic: A 4-in-1 Breakthrough for Lasting Weight Loss
While Ozempic and similar GLP-1 agonists have revolutionized weight management, new research from Tufts University is exploring a novel 4-in-1 peptide that targets four hormone receptors for potentially greater efficacy and fewer side effects, moving closer to the gold standard of bariatric surgery.
6 min read
GLP-1 Medications for Obesity: Experts See a Broader Revolution Ahead
While GLP-1 receptor agonists have significantly advanced obesity treatment, specialists highlight the evolving landscape of comprehensive, personalized care that integrates various therapeutic strategies.
6 min read
Most People Who Stop GLP-1 Drugs Like Ozempic Eventually Restart Treatment
A recent study presented at ENDO 2026 sheds light on the patterns of GLP-1 medication use for type 2 diabetes, revealing that while many patients stop treatment, a substantial number later restart, suggesting a more cyclical rather than permanent discontinuation.
7 min read
Semaglutide Linked to Fewer Bone Fractures Despite Greater Weight Loss
Discover how semaglutide, a popular GLP-1 medication, shows a surprising benefit in a recent study, potentially reducing bone fracture risk even as it aids in substantial weight loss for individuals with type 2 diabetes.
7 min read